New shot could shield breast cancer patients from Chemo's dangerous side effect

NCT ID NCT06711523

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a long-acting injection called PEG-G-CSF to prevent severe neutropenia (dangerously low white blood cell counts) after chemotherapy in 250 women with breast cancer. Participants receive either the test drug or the already-approved Neulasta. The goal is to see if the new injection works as well and is safe, potentially offering another option to reduce infection risk during cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PEG-G-CSF (a long-acting injection to boost white blood cell counts)
What this could lead to
If successful, this could offer a similar option to Neulasta for preventing dangerous drops in white blood cells after chemotherapy, reducing infection risk.
What could go wrong
This is a late-stage trial, but it only includes breast cancer patients on specific chemo regimens. Results may not apply to all cancers or treatments. Side effects like bone pain or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.